Efalizumab
In the US, Efalizumab (efalizumab systemic) is a member of the drug class selective immunosuppressants and is used to treat Psoriasis.
US matches:
Scheme
Rec.INN
ATC (Anatomical Therapeutic Chemical Classification)
L04AA21
CAS registry number (Chemical Abstracts Service)
0214745-43-4
Therapeutic Category
Selective immunosuppressant
Chemical Name
Immunoglobulin G1, anti - (human antigen CD 11a) (human-mouse monoclonal hu 1124 gamma 1 - chain), disulfide with human-mouse monoclonal hu 1124 light chain, dimer (WHO)
Foreign Names
- Efalizumabum (Latin)
- Efalizumab (German)
- Efalizumab (French)
- Efalizumab (Spanish)
Generic Names
- Efalizumab (OS: USAN)
- anti - CD 11a (IS)
- anti - CD 11a MAb (IS)
- hu 1124 (IS)
- Humanized MHM 24 (IS)
Brand Names
- Arzerra
GlaxoSmithKline, Greece - Raptiva
EMD, Canada; Genentech, United States; Merck, Hong Kong; Serono, Argentina; Serono, Israel; Serono, Latvia
International Drug Name Search
Glossary
| Term | Definition |
|---|---|
| IS | Inofficial Synonym |
| OS | Official Synonym |
| Rec.INN | Recommended International Nonproprietary Name (World Health Organization) |
| USAN | United States Adopted Name |
| WHO | World Health Organization |
Click for further information on drug naming conventions and International Nonproprietary Names.
Important Notice: The Drugs.com international database is in BETA release. This means it is still under development and may contain inaccuracies. It is not intended as a substitute for the expertise and judgement of your physician, pharmacist or other healthcare professional. It should not be construed to indicate that the use of any medication in any country is safe, appropriate or effective for you. Consult with your healthcare professional before taking any medication.
